Inhibition of the mTOR pathway: A possible protective role in coronary artery disease

References

• Tarantino G, Saldalamacchia G, Conca P, Arena A. Non-alcoholic fatty liver disease: further expression of the metabolic syndrome. J Gastroenterol Hepatol. 2007;22:293–303.
   PubMed Web of Science ®Google Scholar
• Tarantino G, Conca P, Pasanisi F, Ariello M, Mastrolia M, Arena A, et al. Could inflammatory markers help diagnose nonalcoholic steatohepatitis?Eur J Gastroenterol Hepatol. 2009;21:504–11.
   PubMed Web of Science ®Google Scholar
• Barbato A, Iacone R, Tarantino G, Russo O, Sorrentino P, Avallone S, et al.; Olivetti Heart Study Research Group. Relationships of PAI-1 levels to central obesity and liver steatosis in a sample of adult male population in southern Italy. Intern Emerg Med. 2009;4:315–23.
   Google Scholar
• Lee YS, Li P, Huh JY, Hwang IJ, Lu M, Kim JI, et al. Inflammation is necessary for long-term but not short-term high-fat diet-induced insulin resistance. Diabetes. 2011;60:2474–83.
   PubMed Web of Science ®Google Scholar
• Weston CR, Davis RJ. The JNK signal transduction pathway. Curr Opin Cell Biol. 2007;19:142–9.
   PubMed Web of Science ®Google Scholar
• Cho H, Black SC, Looper D, Shi M, Kelly-Sullivan D, Timofeevski S, et al. Pharmacological characterization of a small molecule inhibitor of c-Jun kinase. Am J Physiol Endocrinol Metab. 2008;295:E1142–51.
   Google Scholar
• Yu XX, Murray SF, Watts L, Booten SL, Tokorcheck J, Monia BP, et al. Reduction of JNK1 expression with antisense oligonucleotide improves adiposity in obese mice. Am J Physiol Endocrinol Metab. 2008; 295:E436–45.
   PubMedGoogle Scholar
• Prieur X, Roszer T, Ricote M. Lipotoxicity in macrophages: evidence from diseases associated with the metabolic syndrome. Biochim Biophys Acta. 2010;1801:327–37.
   Google Scholar
• Hahn C, Orr AW, Sanders JM, Jhaveri KA, Schwartz MA. The subendothelial extracellular matrix modulates JNK activation by flow stress. Circ Res. 2009;104:995–1003.
   Google Scholar
• Baker AR, Harte AL, Howell N, Pritlove DC, Ranasinghe AM, da Silva NF, et al. Epicardial adipose tissue as a source of nuclear factor-kappaB and c-Jun N-terminal kinase mediated inflammation in patients with coronary artery disease. J Clin Endocrinol Metab. 2009;94:261–7.
   PubMed Web of Science ®Google Scholar
• Choi SS, Diehl AM. Hepatic triglyceride synthesis and nonalcoholic fatty liver disease. Curr Opin Lipidol. 2008;19:295–300.
   Google Scholar
• Tarantino G, Savastano S, Colao A, Capone D, Tarantino M, Grimaldi E, et al. Serum Bcl-2 concentrations in overweight-obese subjects with nonalcoholic fatty liver disease?World J Gastroenterol. 2011;17:5280–8.
   Google Scholar
• Tsai J, Qiu W, Kohen-Avramoglu R, Adeli K. MEK-ERK inhibition corrects the defect in VLDL assembly in HepG2 cells: potential role of ERK in VLDL-ApoB100 particle assembly. Arterioscler Thromb Vasc Biol. 2007;27:211–8.
   Google Scholar
• Gubern A, Barceló-Torns M, Barneda D, López JM, Masgrau R, Picatoste F, et al. JNK and ceramide kinase govern the biogenesis of lipid droplets through activation of group IVA phospholipase A2. J Biol Chem. 2009; 284:32359–69.
   Google Scholar
• Nogueira TC, Graciano MF, Anhê GF, Curi R, Bordin S, Carpinelli AR. Short-term modulation of extracellular signal-regulated kinase 1/2 and stress-activated protein kinase/c-Jun NH2-terminal kinase in pancreatic islets by glucose and palmitate: possible involvement of ceramide. Pancreas. 2009;38:585–92.
   Google Scholar
• Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell. 2006;124:471–84.
   PubMed Web of Science ®Google Scholar
• Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell. 2007;12:9–22.
   PubMed Web of Science ®Google Scholar
• Sarbassov DD, Ali SM, Sengupta S, Sheen JH, Hsu PP, Bagley AF, et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell. 2006;22:159–68.
   PubMed Web of Science ®Google Scholar
• Faivre S, Kroemer G, Raymond E. Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov. 2006;5:671–88.
   PubMed Web of Science ®Google Scholar
• Efeyan A, Sabatini DM. mTOR and cancer: many loops in one pathway. Curr Opin Cell Biol. 2010;22:169–76.
   PubMed Web of Science ®Google Scholar
• Petroulakis E, Mamane Y, Le Bacquer O, Shahbazian D, Sonenberg N. mTOR signaling: implications for cancer and anticancer therapy. Br J Cancer. 2006;94;195–99.
   PubMed Web of Science ®Google Scholar
• Joungmok K, Mondira K, Benoit V, Kun-Liang. AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk. Nature Cell Biology. 2011;13:132–41.
   PubMed Web of Science ®Google Scholar
• Qin L, Wang Z, Tao L, Wang Y. ER stress negatively regulates AKT/TSC/mTOR pathway to enhance autophagy. Autophagy. 2010;6:239–47.
   PubMed Web of Science ®Google Scholar
• Gingras AC, Raught B, Sonenberg N. Regulation of translation initiation by FRAP/mTOR. Genes Dev. 2001;15:807–26.
   PubMed Web of Science ®Google Scholar
• Sarbassov DD, Ali SM, Sabatini DM. Growing roles for the mTOR pathway. Curr Opin Cell Biol. 2005;17:596–603.
   PubMed Web of Science ®Google Scholar
• Jang BC, Paik JH, Kim SP, Shin DH, Song DK, Park JG, et al. Catalase induced expression of inflammatory mediators via activation of NF-kappaB, PI3K/AKT, p70S6K, and JNKs in BV2 microglia. Cell Signal. 2005;17:625–33.
   PubMed Web of Science ®Google Scholar
• Guba M, von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, Hornung M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med. 2002;8:128–35.
   PubMed Web of Science ®Google Scholar
• Sandhofer A, Tatarczyk T, Kirchmair R, Iglseder B, Paulweber B, Patsch JR, et al. Are plasma VEGF and its soluble receptor sFlt-1 atherogenic risk factors?Cross-sectional data from the SAPHIR study. Atherosclerosis. 2009;206:265–9.
   PubMed Web of Science ®Google Scholar
• Belgore FM, Blann AD, Lip GY. Measurement of free and complexed soluble vascular endothelial growth factor receptor, Flt-1, in fluid samples: development and application of two new immunoassays. Clin Sci (Lond). 2001;100:567–75.
   PubMed Web of Science ®Google Scholar
• Haruta T, Uno T, Kawahara J, Takano A, Egawa K, Sharma PM, et al. A rapamycin-sensitive pathway down-regulates insulin signaling via phosphorylation and proteasomal degradation of insulin receptor substrate-1. Mol Endocrinol. 2000;14:783–94.
   PubMed Web of Science ®Google Scholar
• Manning BD. Balancing Akt with S6K: implications for both metabolic diseases and tumorigenes. J Cell Biol. 2004;167:399–403.
   PubMed Web of Science ®Google Scholar
• Ginion A, Auquier J, Benton CR, Mouton C, Vanoverschelde JL, Hue L, et al. Inhibition of the mTOR/p70S6K pathway is not involved in the insulin-sensitizing effect of AMPK on cardiac glucose uptake. Am J Physiol Heart Circ Physiol. 2011;301:H469–77.
   Google Scholar
• Cho HJ, Park J, Lee HW, Lee YS, Kim JB. Regulation of adipocyte differentiation and insulin action with rapamycin. Biochem Biophys Res Commun. 2004;321:942–8.
   PubMed Web of Science ®Google Scholar
• Kim JE, Chen J. Regulation of peroxisome proliferator-activated receptor-gamma activity by mammalian target of rapamycin and amino acids in adipogenesis. Diabetes. 2004;53:2748–56.
   PubMed Web of Science ®Google Scholar
• Khamzina L, Veilleux A, Bergeron S, Marette A. Increased activation of the mammalian target of rapamycin pathway in liver and skeletal muscle of obese rats: possible involvement in obesity-linked insulin resistance. Endocrinology. 2005;146:1473–81.
   PubMed Web of Science ®Google Scholar
• Um SH, Frigerio F, Watanabe M, Picard F, Joaquin M, Sticker M, et al. Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity. Nature. 2004;431:200–5.
   PubMed Web of Science ®Google Scholar
• Morice MC, Serrys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, et al.; RAVEL Study Group. Randomized Study with the Sirolimus-Coated Bx Velocity Balloon-Expandable Stent in the Treatment of Patients with de Novo Native Coronary Artery Lesions. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002;346:1773–80.
   PubMed Web of Science ®Google Scholar
• Ma KL, Ruan XZ, Powis SH, Moorhead JF, Varghese Z. Anti-atherosclerotic effects of sirolimus on human vascular smooth muscle cells. Am J Physiol Heart Circ Physiol. 2007;292:H2721–8.
   Web of Science ®Google Scholar
• Schreml S, Lehle K, Birnbaum DE, Preuner JG. mTOR-inhibitors simultaneously inhibit proliferation and basal IL-6 synthesis of human coronary artery endothelial cells. Int Immunopharmacol. 2007;7: 781–90.
   Google Scholar
• Morrisett JD, Abdel-Fattah G, Hoogeveen R , Mitchell E, Ballantyne CM, Pownall HJ, et al. Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients. J Lipid Res. 2002;43:1170–80.
   PubMed Web of Science ®Google Scholar
• Baetta R, Granata A, Canavesi M, Ferri N, Arnaboldi L, Bellosta S, et al. Everolimus inhibitors monocyte/macrophage migration in vitro and their accumulation in carotid lesions of cholesterol-fed rabbits. J Pharmacol Exp Ther. 2009;328:419–25.
   PubMed Web of Science ®Google Scholar
• Gouëffic Y, Potter-Perigo S, Chan CK, Johnson PY, Braun K, Evanko SP, et al. Sirolimus blocks the accumulation of hyaluronan (HA) by arterial smooth muscle cells and reduces monocyte adhesion to the ECM. Atherosclerosis. 2007;195:23–30.
   Web of Science ®Google Scholar
• Waksman R, Pakala R, Burnett MS, Gulick CP, Leborgne L, Fournadjiev J, et al. Oral rapamycin inhibits growth of atherosclerotic plaque in apo E knock-out mice. Cardiovasc Radiat Med. 2003;4:34–8.
   PubMedGoogle Scholar
• Mueller MA, Beutner F, Teupser D, Ceglarek U, Thiery J. Prevention of atherosclerosis by the mTOR inhibitor everolimus in LDLR2/2 mice despite severe hypercholesterolemia. Atherosclerosis. 2008;198:39–48.
   PubMed Web of Science ®Google Scholar
• Chen WQ, Zhong L, Zhang L, Ji XP, Zhang M, Zhao YX, et al. Oral rapamycin attenuates inflammation and enhances stability of atherosclerotic plaques in rabbits independent of serum lipid levels. Br J Pharmacol. 2009;156:941–51.
   PubMed Web of Science ®Google Scholar
• Neal DAJ, Gimson AES, Gibbs P, Alexander AJM. Beneficial effects of converting liver transplant recipients from cyclosporin to tacrolimus on blood pressure, serum lipids and weight. Liver Transpl. 2001;7:533–9.
   PubMed Web of Science ®Google Scholar
• Wawrzynowicz-Syczewska M, Karpińska E, Jurczyk K, Laurans L, Boroń-Kaczmarska A. Risk factors and dynamics of weight gain in patients after liver transplantation. Ann Transplant. 2009;14:45–50.
   Google Scholar
• Richards J, Gunson B, Johnson J, Neuberger J. Weight gain and obesity after liver transplantation. Transpl Int. 2005;18:461–6.
   PubMed Web of Science ®Google Scholar
• Rovira J, Marcelo Arellano E, Burke JT, Brault Y, Moya-Rull D, Bañón-Maneus E, et al. Effect of mTOR inhibitor on body weight: from an experimental rat model to human transplant patients. Transpl Int. 2008;21:992–8.
   Google Scholar
• Inoki K, Ouyang H, Zhu T, Lindvall C, Wang Y, Zhang X, et al. TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth. Cell. 2006;126:955–68.
   PubMed Web of Science ®Google Scholar
• Vigneron F, Dos Santos P, Lemoine S, Bonnet M, Tariosse L, Couffinhal T, et al. GSK-3β at the crossroads in the signalling of heart preconditioning: implication of mTOR and Wnt pathways. Cardiovasc Res. 2011;90:49–56.
   PubMed Web of Science ®Google Scholar
• Alligier M, Meugnier E, Debard C, Lambert-Porcheron S, Chanseaume E, Sothier M, et al. Subcutaneous adipose tissue remodeling during the initial phase of weight gain induced by overfeeding in humans. J Clin Endocrinol Metab. 2012;97:E183–92.
   PubMed Web of Science ®Google Scholar
• Aakhus S, Dahl K, Wideroe TE. Cardiovascular disease in stable renal transplant patients in Norway: morbidity and mortality during a 5-yr follow-up. Clin Transplant. 2004;18:596–604.
   PubMed Web of Science ®Google Scholar
• Kramer NC, Peters TG, Rohr MS, Thacker LR, Vaughn WK. Beneficial effect of cyclosporine on renal transplantation. A multicenter long-term study. Transplantation. 1990;49:343–8.
   Google Scholar
• Jindal RM, Zawada Jr ET. Obesity and kidney transplantation. Am J Kidney Dis. 2004;43:943–52.
   PubMedGoogle Scholar
• Kasiske BL, Chakkera HA, Roel J. Explained and unexplained ischemic heart disease risk after renal transplantation. J Am Soc Nephrol. 2000;11:1735–43.
   PubMed Web of Science ®Google Scholar
• Elmagd MM, Bakr MA, Metwally AH, Wahab AM. Clinicoepidemiologic study of posttransplant diabetes after living-donor renal transplant. Exp Clin Transplant. 2008;6:42–7.
   Google Scholar
• Tarantino G, Palmiero G, Polichetti G, Perfetti A, Sabbatini M, Basile V, et al. Long-term assessment of plasma lipids in transplant recipients treated with tacrolimus in relation to fatty liver. Int J Immunopathol Pharmacol. 2010;23:1303–8.
   Google Scholar
• Augustine JJ, Hricik DE. Minimization of immunosuppression in kidney transplantation. Curr Opin Nephrol Hypertens. 2007;16:535–41.
   Google Scholar
• Sharma NK, Das SK, Mondal AK, Hackney OG, Chu WS, Kern PA, et al. Endoplasmic reticulum stress markers are associated with obesity in nondiabetic subjects. J Clin Endocrinol Metab. 2008;93:4532–41.
   PubMed Web of Science ®Google Scholar
• Boden G, Duan X, Homko C, Molina EJ, Song W, Perez O, et al. Increase in endoplasmic reticulum stress-related proteins and genes in adipose tissue of obese, insulin-resistant individuals. Diabetes. 2008;57:2438–44.
   PubMed Web of Science ®Google Scholar
• Vendrell J, Maymó-Masip E, Tinahones F, García-España A, Megia A, Caubet E, et al. Tumor necrosis-like weak inducer of apoptosis as a proinflammatory cytokine in human adipocyte cells: up-regulation in severe obesity is mediated by inflammation but not hypoxia. J Clin Endocrinol Metab. 2010;95:2983–92.
   PubMed Web of Science ®Google Scholar
• Gregor MF, Yang L, Fabbrini E, Mohammed BS, Eagon JC, Hotamisligil GS, et al. Endoplasmic reticulum stress is reduced in tissues of obese subjects after weight loss. Diabetes. 2009;58:693–700.
   PubMed Web of Science ®Google Scholar
• Alhusaini S, McGee K, Schisano B, Harte A, McTernan P, Kumar S, et al. Lipopolysaccharide, high glucose and saturated fatty acids induce endoplasmic reticulum stress in cultured primary human adipocytes: salicylate alleviates this stress. Biochem Biophys Res Commun. 2010; 397:472–8.
   Google Scholar
• Jiao P, Ma J, Feng B, Zhang H, Alan Diehl J, Eugene Chin Y, et al. FFA-induced adipocyte inflammation and insulin resistance: involvement of ER stress and IKKb pathways. Obesity (Silver Spring). 2011; 19:483–91.
   Google Scholar
• Zhou QG, Zhou M, Hou FF, Peng X. Asymmetrical dimethylarginine triggers lipolysis and inflammatory response via induction of endoplasmic reticulum stress in cultured adipocytes. Am J Physiol Endocrinol Metab. 2009;296:E869–78.
   Google Scholar
• Zhou L, Liu M, Zhang J, Chen H, Dong LQ, Liu F. DsbA-L alleviates endoplasmic reticulum stress-induced adiponectin downregulation. Diabetes. 2010;59:2809–16.
   PubMed Web of Science ®Google Scholar
• Xu L, Spinas GA, Niessen M. ER stress in adipocytes inhibits insulin signaling, represses lipolysis, and alters the secretion of adipokines without inhibiting glucose transport. Horm Metab Res. 2010;42:643–51.
   PubMed Web of Science ®Google Scholar
• Lefterova MI, Mullican SE, Tomaru T, Qatanani M, Schupp M, Lazar MA. Endoplasmic reticulum stress regulates adipocyte resistin expression. Diabetes. 2009;58:1879–86.
   Google Scholar
• Ye R, Jung DY, Jun JY, Li J, Luo S, Ko HJ, et al. Grp78 heterozygosity promotes adaptive unfolded protein response and attenuates diet-induced obesity and insulin resistance. Diabetes. 2010;59:6–16.
   PubMed Web of Science ®Google Scholar
• da Luz G, Frederico MJ, da Silva S, Vitto MF, Cesconetto PA, de Pinho RA, et al. Endurance exercise training ameliorates insulin resistance and reticulum stress in adipose and hepatic tissue in obese rats. Eur J Appl Physiol. 2011;111:2015–23.
   PubMed Web of Science ®Google Scholar
• Cretenet G, Le Clech M, Gachon F. Circadian clock-coordinated 12 hr period rhythmic activation of the IRE1a pathway controls lipid metabolism in mouse liver. Cell Metab. 2010;11:47–57.
   PubMed Web of Science ®Google Scholar
• Oyadomari S, Harding HP, Zhang Y, Oyadomari M, Ron D. Dephosphorylation of translation initiation factor 2a enhances glucose tolerance and attenuates hepatosteatosis in mice. Cell Metab. 2008;7;520–32.
   PubMed Web of Science ®Google Scholar
• Puri P, Mirshahi F, Cheung O, Natarajan R, Maher JW, Kellum JM, et al. Activation and dysregulation of the unfolded protein response in nonalcoholic fatty liver disease. Gastroenterology. 2008;134:568–76.
   PubMed Web of Science ®Google Scholar
• Yang L, Li P, Fu S, Calay ES, Hotamisligil GS. Defective hepatic autophagy in obesity promotes ER stress and causes insulin resistance. Cell Metab. 2010;11:467–78.
   PubMed Web of Science ®Google Scholar
• Kammoun HL, Chabanon H, Hainault I, Luquet S, Magnan C, Koike T, et al. GRP78 expression inhibits insulin and ER stress-induced SREBP-1c activation and reduces hepatic steatosis in mice. J Clin Invest. 2009: 119;1201–15.
   PubMed Web of Science ®Google Scholar
• Boulbés DR, Shaiken T, Sarbassov dos D. Endoplasmic reticulum is a main localization site of mTORC2. Biochem Biophys Res Commun. 2011;413:46–52.
   Google Scholar